Abstract
Summary
The Europe acute respiratory distress syndrome (ARDS) treatment market is expected to reach USD 2,764,971.40 thousand by 2030, from USD 1,356,879.02 thousand in 2022, growing at the CAGR of 9.7% in the forecast period of 2023 to 2030.
Market Segmentation
Europe Acute Respiratory Distress Syndrome (Ards) Treatment Market, By Type (Mechanical Ventilation, Corticosteroids, Antiviral Medication, Extracorporeal Membrane Oxygenation (ECMO), Tocilizumab, and Others), Cause ( Sepsis, Inhalation of Harmful Substances, Severe Pneumonia, and Others), Route of Administration (Parenteral, Oral, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country (Germany, France, U.K., Italy, Spain, Turkey, Hungary, Netherlands, Switzerland, Austria Lithuania, Poland, Russia, Ireland, Norway, and rest of Europe) - Industry Trends and Forecast to 2030.
Overview of Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Dynamics
Driver
• Increasing prevalence and incidence of acute lung injury in the market
Restraint
• High cost of device and treatment
Opportunity
• Strategic initiatives joined with new product launches by market players
Market Players
Some of the major market players operating in the Europe Acute Respiratory Distress Syndrome (ARDS) market are listed below:
• Gilead Sciences, Inc.
• Terumo Medical Corporation
• Getinge AB.
• LivaNova PLC
• Medtronic
• ResMed
• Fisher & Paykel Healthcare Limited.
• Drägerwerk AG & Co. KGaA
• NIPRO
• Fresenius SE & Co. KGaA
• Hamilton Medical
• Pfizer Inc.
• WEINMANN Emergency Medical Technology GmbH + Co. KG
• EUROSETS
• Armstrong Medical
• nice Neotech Medical Systems Pvt. Ltd.
• Besmed Health Business Corp.
Table of Contents
1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 OVERVIEW OF EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 22
1.4 LIMITATIONS 24
1.5 MARKETS COVERED 24
2 MARKET SEGMENTATION 26
2.1 MARKETS COVERED 26
2.2 GEOGRAPHICAL SCOPE 27
2.3 YEARS CONSIDERED FOR THE STUDY 28
2.4 CURRENCY AND PRICING 28
2.5 DBMR TRIPOD DATA VALIDATION MODEL 29
2.6 MULTIVARIATE MODELLING 32
2.7 TYPE LIFELINE CURVE 32
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 33
2.9 DBMR MARKET POSITION GRID 34
2.10 MARKET END USER COVERAGE GRID 35
2.11 VENDOR SHARE ANALYSIS 36
2.12 SECONDARY SOURCES 37
2.13 ASSUMPTIONS 37
3 EXECUTIVE SUMMARY 38
4 PREMIUM INSIGHTS 41
4.1 PESTEL ANALYSIS 42
4.2 PORTER’S FIVE FORCES 43
4.3 INSURANCE REIMBURSEMENT 44
4.3.1 CENTER FOR MEDICARE SERVICES (CMS)-ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION) 44
4.3.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION 44
4.3.3 ABBOTT CODING GUIDE FOR ECMO 45
4.3.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS) 45
4.3.5 CERN HEALTH INSURANCE SCHEME 46
4.3.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) - (MEDICARE & MEDICAID) 46
4.3.7 AMERICAN HOSPITAL ASSOCIATION 47
4.4 PIPELINE ANALYSIS 48
4.5 PRICING ANALYSIS 50
5 MARKET OVERVIEW 51
5.1 DRIVERS 53
5.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY 53
5.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS TREATMENT 53
5.1.3 RISING RATE OF AIR POLLUTION AND UNHEALTHY LIFESTYLE 54
5.1.4 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS 54
5.2 RESTRAINTS 55
5.2.1 COMPLICATIONS ASSOCIATED WITH THE TREATMENT 55
5.2.2 HIGH COST OF DEVICES AND TREATMENT 55
5.3 OPPORTUNITIES 56
5.3.1 RISING HEALTHCARE EXPENDITURE TO IMPROVE TREATMENT FACILITIES 56
5.3.2 STRATEGIC INITIATIVES JOINED WITH NEW PRODUCT LAUNCH BY MARKET PLAYERS 56
5.3.3 IMPROVING AWARENESS REGARDING ARD SYNDROME 57
5.4 CHALLENGES 58
5.4.1 STRINGENT RULES & REGULATIONS 58
5.4.2 MULTIPLE CHALLENGES FACED BY ICU STAFF 59
6 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE 60
6.1 OVERVIEW 61
6.2 MECHANICAL VENTILATION 64
6.2.1 HIGH-FLOW NASAL O2 65
6.2.2 BI-LEVEL POSITIVE AIRWAY PRESSURE 65
6.2.3 CONTINUOUS POSITIVE AIRWAY PRESSURE 65
6.2.4 PRONE POSITION VENTILATION 65
6.2.5 OTHERS 66
6.3 CORTICOSTEROIDS 66
6.3.1 METHYLPREDNISOLONE 67
6.3.2 DEXAMETHASONE 67
6.3.3 OTHERS 67
6.4 ANTIVIRAL MEDICATION 68
6.4.1 RIBAVIRIN 69
6.4.2 OSELTAMIVIR 69
6.4.3 OTHERS 69
6.5 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 69
6.6 TOCILIZUMAB 70
6.7 OTHERS 70
7 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE 71
7.1 OVERVIEW 72
7.2 SEPSIS 75
7.3 INHALATION OF HARMFUL SUBSTANCES 75
7.4 SEVERE PNEUMONIA 76
7.5 OTHERS 76
8 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 77
8.1 OVERVIEW 78
8.2 PARENTERAL 81
8.2.1 INTRAVENOUS 81
8.2.2 INTRAMUSCULAR 81
8.3 ORAL 82
8.4 OTHERS 82
9 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER 83
9.1 OVERVIEW 84
9.2 HOSPITALS 87
9.3 SPECIALTY CLINICS 87
9.4 HOME HEALTHCARE 88
9.5 OTHERS 88
10 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 89
10.1 OVERVIEW 90
10.2 DIRECT TENDER 93
10.3 HOSPITAL PHARMACY 93
10.4 RETAIL PHARMACY 94
10.5 ONLINE PHARMACY 94
11 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION 95
11.1 EUROPE 97
11.1.1 GERMANY 102
11.1.2 FRANCE 107
11.1.3 U.K 112
11.1.4 ITALY 117
11.1.5 SPAIN 122
11.1.6 TURKEY 127
11.1.7 NETHERLANDS 132
11.1.8 SWITZERLAND 137
11.1.9 BELGIUM 142
11.1.10 RUSSIA 147
11.1.11 REST OF EUROPE 152
12 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, COMPANY LANDSCAPE 153
12.1 COMPANY SHARE ANALYSIS: EUROPE 153
13 SWOT ANALYSIS 154
14 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT, CPS 155
14.1 GILEAD SCIENCES INC 155
14.1.1 COMPANY SNAPSHOT 155
14.1.2 REVENUE ANALYSIS 156
14.1.3 COMPANY SHARE ANALYSIS 156
14.1.4 PRODUCT PORTFOLIO 157
14.1.5 RECENT DEVELOPMENT 157
14.2 TERUMO CORPORATION 158
14.2.1 COMPANY SNAPSHOT 158
14.2.2 REVENUE ANALYSIS 158
14.2.3 COMPANY SHARE ANALYSIS 159
14.2.4 PRODUCT PORTFOLIO 159
14.2.5 RECENT DEVELOPMENT 159
14.3 GETINGE 160
14.3.1 COMPANY SNAPSHOT 160
14.3.2 REVENUE ANALYSIS 160
14.3.3 COMPANY SHARE ANALYSIS 161
14.3.4 PRODUCT PORTFOLIO 161
14.3.5 RECENT DEVELOPMENT 161
14.4 LIVANOVA PLC 162
14.4.1 COMPANY SNAPSHOT 162
14.4.2 REVENUE ANALYSIS 162
14.4.3 COMPANY SHARE ANALYSIS 163
14.4.4 PRODUCT PORTFOLIO 163
14.4.5 RECENT DEVELOPMENTS 163
14.5 MEDTRONIC 164
14.5.1 COMPANY SNAPSHOT 164
14.5.2 REVENUE ANALYSIS 164
14.5.3 COMPANY SHARE ANALYSIS 165
14.5.4 PRODUCT PORTFOLIO 165
14.5.5 RECENT DEVELOPMENTS 165
14.6 ARMSTRONG MEDICAL 166
14.6.1 COMPANY SNAPSHOT 166
14.6.2 PRODUCT PORTFOLIO 166
14.6.3 RECENT DEVELOPMENT 166
14.7 BESMED HEALTH BUSINESS CORP 167
14.7.1 COMPANY SNAPSHOT 167
14.7.2 PRODUCT PORTFOLIO 167
14.7.3 RECENT DEVELOPMENTS 168
14.8 DRÄGERWERK AG & CO. KGAA 169
14.8.1 COMPANY SNAPSHOT 169
14.8.2 REVENUE ANALYSIS 169
14.8.3 PRODUCT PORTFOLIO 170
14.8.4 RECENT DEVELOPMENTS 170
14.9 EUROSETS 171
14.9.1 COMPANY SNAPSHOT 171
14.9.2 PRODUCT PORTFOLIO 171
14.9.3 RECENT DEVELOPMENT 171
14.10 FISHER & PAYKEL HEALTHCARE LIMITED 172
14.10.1 COMPANY SNAPSHOT 172
14.10.2 REVENUE ANALYSIS 172
14.10.3 PRODUCT PORTFOLIO 173
14.10.4 RECENT DEVELOPMENTS 173
14.11 FRESENIUS SE & CO. KGAA 174
14.11.1 COMPANY SNAPSHOT 174
14.11.2 REVENUE ANALYSIS 174
14.11.3 PRODUCT PORTFOLIO 175
14.11.4 RECENT DEVELOPMENT 175
14.12 HAMILTON MEDICAL 176
14.12.1 COMPANY SNAPSHOT 176
14.12.2 PRODUCT PORTFOLIO 176
14.12.3 RECENT DEVELOPMENT 176
14.13 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD 177
14.13.1 COMPANY SNAPSHOT 177
14.13.2 PRODUCT PORTFOLIO 177
14.13.3 RECENT DEVELOPMENT 177
14.14 NIPRO 178
14.14.1 COMPANY SNAPSHOT 178
14.14.2 REVENUE ANALYSIS 178
14.14.3 PRODUCT PORTFOLIO 179
14.14.4 RECENT DEVELOPMENT 179
14.15 PFIZER INC 180
14.15.1 COMPANY SNAPSHOT 180
14.15.2 REVENUE ANALYSIS 180
14.15.3 PRODUCT PORTFOLIO 181
14.15.4 RECENT DEVELOPMENT 181
14.16 RESMED 182
14.16.1 COMPANY SNAPSHOT 182
14.16.2 REVENUE ANALYSIS 182
14.16.3 PRODUCT PORTFOLIO 183
14.16.4 RECENT DEVELOPMENT 183
14.17 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG 184
14.17.1 COMPANY SNAPSHOT 184
14.17.2 PRODUCT PORTFOLIO 184
14.17.3 RECENT DEVELOPMENT 184
15 QUESTIONNAIRE 185
16 RELATED REPORTS 188